Journal: American journal of physiology. Cell physiology

Article Title: Five months of voluntary wheel running downregulates skeletal muscle LINE-1 gene expression in rats

doi: 10.1152/ajpcell.00301.2019

Figure Lengend Snippet: Cell culture experiments to determine possible exercise-specific pathways that regulate long interspersed element-1 (L1) mRNA expression in rat L6 myotubes. A and B: mRNA expression for L1-Tot (A) and L1–3 (B) following 3-h treatments with a variety of drugs described in Table 2 (n = 4 wells/drug/vehicle treatment). C: phosphorylation of AMP-activated protein kinase (AMPK; Thr172) with increasing doses of 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) along with an accompanying Western blot representative image. D and E: effects of different AICAR doses on L1-Tot (D) and L1–3 (E) mRNA expression. F and G: L1-Tot (F) and L1–3 methylation (G) measured via methylated DNA immunoprecipitation (MeDIP). Data in A–G are presented as individual values, and all treatments were statistically compared with the DMSO control (DMSO presented as solid line at 1.0 ± SD; n = 6 wells/AICAR/vehicle treatment in C–G). 5-AZA, 5-azacytidine; CAF, caffeine; RES, resveratrol; ROT, rotenone; TA, trichostatin A. 1, 2, and 4 mM refer to the increasing concentrations of AICAR.

Article Snippet: Drug treatments for in vitro screening Treatments included AICAR (1 mM, cat. no. BML-EI330; Enzo, Farmingdale, NY), caffeine (5 mM, cat. no. A10431; Alfa Aesar, Ward Hill, MA), rotenone (100 nM, cat. no. ALX350360G001; Enzo), resveratrol (10 μM, cat. no. R0071; TCI America, Portland, OR), the global HDAC inhibitor trichostatin A (100 nM, cat. no. G656A; Promega, Madison, WI), 5-azacytidine (10 μM, TCI America), or 0.1% DMSO (cat. no. 25–950-CQC; Corning Inc., Corning, NY) as a vehicle control.

Techniques: Cell Culture, Expressing, Western Blot, Methylation, Immunoprecipitation, Methylated DNA Immunoprecipitation

Journal: American journal of physiology. Cell physiology

Article Title: Five months of voluntary wheel running downregulates skeletal muscle LINE-1 gene expression in rats

doi: 10.1152/ajpcell.00301.2019

Figure Lengend Snippet: Drug treatments for in vitro screening

Article Snippet: Drug treatments for in vitro screening Treatments included AICAR (1 mM, cat. no. BML-EI330; Enzo, Farmingdale, NY), caffeine (5 mM, cat. no. A10431; Alfa Aesar, Ward Hill, MA), rotenone (100 nM, cat. no. ALX350360G001; Enzo), resveratrol (10 μM, cat. no. R0071; TCI America, Portland, OR), the global HDAC inhibitor trichostatin A (100 nM, cat. no. G656A; Promega, Madison, WI), 5-azacytidine (10 μM, TCI America), or 0.1% DMSO (cat. no. 25–950-CQC; Corning Inc., Corning, NY) as a vehicle control.

Techniques: In Vitro, Concentration Assay, Activity Assay

Journal: American journal of physiology. Cell physiology

Article Title: Five months of voluntary wheel running downregulates skeletal muscle LINE-1 gene expression in rats

doi: 10.1152/ajpcell.00301.2019

Figure Lengend Snippet: Cell culture experiments to determine possible exercise-specific pathways that regulate long interspersed element-1 (L1) mRNA expression in rat L6 myotubes. A and B: mRNA expression for L1-Tot (A) and L1–3 (B) following 3-h treatments with a variety of drugs described in Table 2 (n = 4 wells/drug/vehicle treatment). C: phosphorylation of AMP-activated protein kinase (AMPK; Thr172) with increasing doses of 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) along with an accompanying Western blot representative image. D and E: effects of different AICAR doses on L1-Tot (D) and L1–3 (E) mRNA expression. F and G: L1-Tot (F) and L1–3 methylation (G) measured via methylated DNA immunoprecipitation (MeDIP). Data in A–G are presented as individual values, and all treatments were statistically compared with the DMSO control (DMSO presented as solid line at 1.0 ± SD; n = 6 wells/AICAR/vehicle treatment in C–G). 5-AZA, 5-azacytidine; CAF, caffeine; RES, resveratrol; ROT, rotenone; TA, trichostatin A. 1, 2, and 4 mM refer to the increasing concentrations of AICAR.

Article Snippet: Drug treatments for in vitro screening Treatments included AICAR (1 mM, cat. no. BML-EI330; Enzo, Farmingdale, NY), caffeine (5 mM, cat. no. A10431; Alfa Aesar, Ward Hill, MA), rotenone (100 nM, cat. no. ALX350360G001; Enzo), resveratrol (10 μM, cat. no. R0071; TCI America, Portland, OR), the global HDAC inhibitor trichostatin A (100 nM, cat. no. G656A; Promega, Madison, WI), 5-azacytidine (10 μM, TCI America), or 0.1% DMSO (cat. no. 25–950-CQC; Corning Inc., Corning, NY) as a vehicle control.

Techniques: Cell Culture, Expressing, Western Blot, Methylation, Immunoprecipitation, Methylated DNA Immunoprecipitation